218 related articles for article (PubMed ID: 34162346)
1. Gliosarcoma vs. glioblastoma: a retrospective case series using molecular profiling.
Dardis C; Donner D; Sanai N; Xiu J; Mittal S; Michelhaugh SK; Pandey M; Kesari S; Heimberger AB; Gatalica Z; Korn MW; Sumrall AL; Phuphanich S
BMC Neurol; 2021 Jun; 21(1):231. PubMed ID: 34162346
[TBL] [Abstract][Full Text] [Related]
2. Clinical and molecular characteristics of gliosarcoma and modern prognostic significance relative to conventional glioblastoma.
Smith DR; Wu CC; Saadatmand HJ; Isaacson SR; Cheng SK; Sisti MB; Bruce JN; Sheth SA; Lassman AB; Iwamoto FM; Wang SH; Canoll P; McKhann GM; Wang TJC
J Neurooncol; 2018 Apr; 137(2):303-311. PubMed ID: 29264835
[TBL] [Abstract][Full Text] [Related]
3. High prevalence of TP53 mutations is associated with poor survival and an EMT signature in gliosarcoma patients.
Cho SY; Park C; Na D; Han JY; Lee J; Park OK; Zhang C; Sung CO; Moon HE; Kim Y; Kim JH; Kim JJ; Khang SK; Nam DH; Choi JW; Suh YL; Kim DG; Park SH; Youn H; Yun K; Kim JI; Lee C; Paek SH; Park H
Exp Mol Med; 2017 Apr; 49(4):e317. PubMed ID: 28408749
[TBL] [Abstract][Full Text] [Related]
4. Primary and secondary gliosarcomas: clinical, molecular and survival characteristics.
Cachia D; Kamiya-Matsuoka C; Mandel JJ; Olar A; Cykowski MD; Armstrong TS; Fuller GN; Gilbert MR; De Groot JF
J Neurooncol; 2015 Nov; 125(2):401-10. PubMed ID: 26354773
[TBL] [Abstract][Full Text] [Related]
5. Expression of CD70 (CD27L) Is Associated With Epithelioid and Sarcomatous Features in IDH-Wild-Type Glioblastoma.
Pratt D; Pittaluga S; Palisoc M; Fetsch P; Xi L; Raffeld M; Gilbert MR; Quezado M
J Neuropathol Exp Neurol; 2017 Aug; 76(8):697-708. PubMed ID: 28789475
[TBL] [Abstract][Full Text] [Related]
6. Amplification of the STOML3, FREM2, and LHFP genes is associated with mesenchymal differentiation in gliosarcoma.
Nagaishi M; Kim YH; Mittelbronn M; Giangaspero F; Paulus W; Brokinkel B; Vital A; Tanaka Y; Nakazato Y; Legras-Lachuer C; Lachuer J; Ohgaki H
Am J Pathol; 2012 May; 180(5):1816-23. PubMed ID: 22538188
[TBL] [Abstract][Full Text] [Related]
7. Transformation of IDH-wildtype glioblastoma to gliosarcoma with features of osteosarcoma.
Sobczyk P; Sobstyl M; Acewicz A; Rosa J; Grabiec M; Grajkowska W
Folia Neuropathol; 2024; 62(1):96-101. PubMed ID: 38741436
[TBL] [Abstract][Full Text] [Related]
8. Clinical outcome of gliosarcoma compared with glioblastoma multiforme: a clinical study in Chinese patients.
Zhang G; Huang S; Zhang J; Wu Z; Lin S; Wang Y
J Neurooncol; 2016 Apr; 127(2):355-62. PubMed ID: 26725096
[TBL] [Abstract][Full Text] [Related]
9. Gliosarcomas lack BRAF
Schwetye KE; Joseph NM; Al-Kateb H; Rich KM; Schmidt RE; Perry A; Gutmann DH; Dahiya S
Neuropathology; 2016 Oct; 36(5):448-455. PubMed ID: 26932501
[TBL] [Abstract][Full Text] [Related]
10. Epithelial and pseudoepithelial differentiation in glioblastoma and gliosarcoma: a comparative morphologic and molecular genetic study.
Rodriguez FJ; Scheithauer BW; Giannini C; Bryant SC; Jenkins RB
Cancer; 2008 Nov; 113(10):2779-89. PubMed ID: 18816605
[TBL] [Abstract][Full Text] [Related]
11. Can a signature molecular-profile define disparate survival in BRAF-positive Gliosarcoma and identify novel targets for therapeutic intervention?
Gandhi P; Khare R; Garg N; Mishra J
J Cancer Res Ther; 2022; 18(1):224-230. PubMed ID: 35381788
[TBL] [Abstract][Full Text] [Related]
12. Patterns of care and outcomes in gliosarcoma: an analysis of the National Cancer Database.
Frandsen J; Orton A; Jensen R; Colman H; Cohen AL; Tward J; Shrieve DC; Suneja G
J Neurosurg; 2018 Apr; 128(4):1133-1138. PubMed ID: 28621623
[TBL] [Abstract][Full Text] [Related]
13. Sarcoma arising as a distinct nodule within glioblastoma: a morphological and molecular perspective on gliosarcoma.
Jimenez C; Powers M; Parsa AT; Glastonbury C; Hagenkord JM; Tihan T
J Neurooncol; 2011 Nov; 105(2):317-23. PubMed ID: 21533839
[TBL] [Abstract][Full Text] [Related]
14. Gliosarcoma with prominent smooth muscle component (gliomyosarcoma): a report of 10 cases.
Khanna M; Siraj F; Chopra P; Bhalla S; Roy S
Indian J Pathol Microbiol; 2011; 54(1):51-4. PubMed ID: 21393877
[TBL] [Abstract][Full Text] [Related]
15. Expression of activated epidermal growth factor receptors, Ras-guanosine triphosphate, and mitogen-activated protein kinase in human glioblastoma multiforme specimens.
Feldkamp MM; Lala P; Lau N; Roncari L; Guha A
Neurosurgery; 1999 Dec; 45(6):1442-53. PubMed ID: 10598712
[TBL] [Abstract][Full Text] [Related]
16. Gliosarcoma: The Distinct Genomic Alterations Identified by Comprehensive Analysis of Copy Number Variations.
Cheng CD; Chen C; Wang L; Dong YF; Yang Y; Chen YN; Niu WX; Wang WC; Liu QS; Niu CS
Anal Cell Pathol (Amst); 2022; 2022():2376288. PubMed ID: 35757013
[TBL] [Abstract][Full Text] [Related]
17. Gliosarcoma with ependymal and PNET-like differentiation.
Shintaku M; Yoneda H; Hirato J; Nagaishi M; Okabe H
Clin Neuropathol; 2013; 32(6):508-14. PubMed ID: 23863343
[TBL] [Abstract][Full Text] [Related]
18. Gliosarcoma with osteosarcomatous component: A case report and short review illustration.
Chen Y; Zhou S; Zhou X; Dai X; Wang L; Chen P; Zhao S; Shi C; Xiao S; Dong J
Pathol Res Pract; 2022 Apr; 232():153837. PubMed ID: 35278815
[TBL] [Abstract][Full Text] [Related]
19. Genetic and pathologic evolution of early secondary gliosarcoma.
Codispoti KE; Mosier S; Ramsey R; Lin MT; Rodriguez FJ
Brain Tumor Pathol; 2014 Jan; 31(1):40-6. PubMed ID: 23324827
[TBL] [Abstract][Full Text] [Related]
20. Tenascin-C protein is induced by transforming growth factor-beta1 but does not correlate with time to tumor progression in high-grade gliomas.
Hau P; Kunz-Schughart LA; Rümmele P; Arslan F; Dörfelt A; Koch H; Lohmeier A; Hirschmann B; Müller A; Bogdahn U; Bosserhoff AK
J Neurooncol; 2006 Mar; 77(1):1-7. PubMed ID: 16292494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
